Abstract
The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for diagnosis, staging and detection of residual/recurrent cancer. However, there are limits to the utility of FDG, particularly in certain tumour types. The development of new radiotracers to study molecular processes such as proliferation, apoptosis, angiogenesis and hypoxia will complement FDG by providing additional information on the cell biology of tumours. The aim of this paper is to consider how the availability of new tracers, or new applications for existing PET/CT technologies, could deliver clinical benefit in cancer, using breast cancer as a paradigm.
| Original language | English |
|---|---|
| Pages (from-to) | 144-152 |
| Number of pages | 9 |
| Journal | Cancer Imaging |
| Volume | 10 |
| Issue number | 1 |
| Publication status | Published - 6 Jul 2010 |
Keywords
- assessing therapy response
- breast cancer
- diagnosis
- identification of recurrence
- pharmacological biomarker
- positron emission tomography
- predictive biomarker
- staging
- surrogate response biomarker
- tumour subtyping
Fingerprint Dive into the research topics of 'Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm'. Together they form a unique fingerprint.
Cite this
Fleming, I. N., Gilbert, F. J., Miles, K. A., & Cameron, D. (2010). Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. Cancer Imaging, 10(1), 144-152. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904028/pdf/ci100020.pdf